The DOI matches its Crossref record.
Hematologic Toxicity of Sodium Valproate
Abstract
PURPOSE: Sodium valproate is a commonly used anticonvulsant in the management of childhood refractory epilepsy with good response rates and acceptable toxicity. Hepatotoxicity is the most widely recognized toxicity. With the use of higher drug levels to achieve adequate seizure control, hematologic toxicity is being increasingly encountered, and the pediatric hematologist is consulted for these problems in the pre- or perioperative setting. The purpose of this article is to characterize the various hematologic toxicities encountered in a clinical setting and to provide guidelines to assist in the management of these patients. METHODS: A literature review was undertaken to identify the hematologic toxicities of valproate used as monotherapy or polytherapy. Key words used in the search were valproate, hematology, and bleeding. RESULTS: Valproate can cause direct bone marrow suppression leading to aplastic anemia or peripheral cytopenia affecting one or more cell lines. Occasional fatal bone marrow failure, myelodysplasia, and a clinical picture resembling acute promyelocytic leukemia have also been seen. Thrombocytopenia, macrocytosis, neutropenia, and pure red cell aplasia can occur but are not reported to be life-threatening. A bleeding diathesis associated with valproate use may include thrombocytopenia, abnormal platelet function, and acquired von Willebrand disease type I. CONCLUSIONS: Hematologic toxicities of valproate are common, vary in onset and severity, are recurrent, transient, or persistent, and usually occur with a serum valproate level greater than 100 microg/mL. In most situations, even when highly clinically significant, they can be reversed with dosage reduction; drug discontinuation is rarely required. Potential adverse effects such as thrombocytopenia and leukopenia are easily detected by laboratory monitoring, which should be continued indefinitely at least on a quarterly basis. Caution for elective surgery is advised; preoperative coagulation studies should be done, including platelet function studies and von Willebrand factor levels. Perioperative use of DDAVP to increase von Willebrand factor levels and improve platelet function is appropriate in some cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management
van Breemen, M. S., Wilms, E. B., & Vecht, C. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70103-5 · Cited by 913
Perucca, E. (2002) · CNS Drugs · doi:10.2165/00023210-200216100-00004 · Cited by 690
Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences
Romoli, M., Mazzocchetti, P., D'Alonzo, R., Siliquini, S., Rinaldi, V. E., Verrotti, A., Calabresi, P., & Costa, C. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666181227165722 · Cited by 372
Valproate: Past, Present, and Future
Johannessen, C. U., & Johannessen, S. I. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00249.x · Cited by 363
Treatment of Typical Absence Seizures and Related Epileptic Syndromes
Panayiotopoulos, C. P. (2001) · Paediatric Drugs · doi:10.2165/00128072-200103050-00006 · Cited by 311
Metadata
- Authors
- Acharya, S., & Bussel, J. B.
- Venue
- Journal of Pediatric Hematology/Oncology
- Published
- 2000-01
- Volume
- 22
- Issue
- 1
- Pages
- 62-65
- ISSN
- 0192-8562 (ISSN-L)
- OpenAlex
- W2047889627
- Cited by
- 220
- References
- 0
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hematologic Toxicity of Sodium Valproate. https://app.cochat.ai/papers/10.1097/00043426-200001000-00012
- The paper
- Acharya, S., & Bussel, J. B. (2000). Hematologic Toxicity of Sodium Valproate. Journal of Pediatric Hematology/Oncology. https://doi.org/10.1097/00043426-200001000-00012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.